Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

Hadassah Researchers Identify Connection Between National Killer Cell and Cirrhosis


Dr. Rifaat Safadi, head of Hadassah's Liver Unit

Researchers at the Hadassah University Medical Center have discovered that over expression of an immune system Natural Killer (NK) cell called Neuroligin 4 can trigger cirrhosis of the liver by preventing the body from combating scarring. The Hadassah study compared blood samples from dozens of patients with cirrhosis to those of a healthy control group. "In their healthy form, the Neuroligin cells kill the scar-tissue cells," reports Prof. Rifaat Safadi, head of Hadassah's Liver Unit and this study. In the over expression scenario, he explains, "a mechanism is put into operation that keeps the cells from doing their unscarring work."

Several years ago, the same research team found that intact NK cells are good for the liver and prevent cirrhosis. The finding was published in the February 2006 issue of The Journal of Hepatology and also reported by a group of researchers at the National Institutes of Health in the United States. Next, Hadassah's researchers plan to investigate whether mutations of Neuroligin 4 also increase the risk of cirrhosis.

Hadasit, Hadassah's Technology Transfer Company, has already patented Neuroligin 4 in hopes of using it to develop treatments to fend off liver disease.


Read the story in Haaretz here>>

Date: 3/19/2013


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America